199 related articles for article (PubMed ID: 29287600)
1. Pulmonary arterial hypertension in a patient treated with dasatinib: a case report.
Skride A; Sablinskis M; Sablinskis K; Lesina K; Lejnieks A; Lejniece S
J Med Case Rep; 2017 Dec; 11(1):362. PubMed ID: 29287600
[TBL] [Abstract][Full Text] [Related]
2. [Reversible dasatinib-related pulmonary arterial hypertension in a CML patient].
Nagasaki J; Aoyama Y; Nomoto Y; Ido K; Ichihara H; Mugitani A
Rinsho Ketsueki; 2016 May; 57(5):618-23. PubMed ID: 27263788
[TBL] [Abstract][Full Text] [Related]
3. [Repeated partially reversible pulmonary arterial hypertension related to dasatinib: a case report and literature review].
Jin J; Xu XM; Wang C
Zhonghua Jie He He Hu Xi Za Zhi; 2016 Feb; 39(2):83-7. PubMed ID: 26879609
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib-induced pulmonary arterial hypertension - A rare late complication.
Ibrahim U; Saqib A; Dhar V; Odaimi M
J Oncol Pharm Pract; 2019 Apr; 25(3):727-730. PubMed ID: 29343154
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Shah NP; Wallis N; Farber HW; Mauro MJ; Wolf RA; Mattei D; Guha M; Rea D; Peacock A
Am J Hematol; 2015 Nov; 90(11):1060-4. PubMed ID: 26284693
[TBL] [Abstract][Full Text] [Related]
6. [Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia].
Morishita S; Hagihara M; Itabashi M; Ishii Y; Yamamoto W; Numata A; Motohashi K; Matsumoto K; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2016 Aug; 57(8):999-1003. PubMed ID: 27599415
[TBL] [Abstract][Full Text] [Related]
7. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Maral S; Bakanay SM; Kucuksahin O; Dilek I
J Oncol Pharm Pract; 2020 Apr; 26(3):738-741. PubMed ID: 31359838
[TBL] [Abstract][Full Text] [Related]
8. [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
Edahiro Y; Takaku T; Konishi H; Tsukune Y; Fujioka I; Takasu K; Gotoh A; Daida H; Komatsu N
Rinsho Ketsueki; 2017; 58(11):2213-2218. PubMed ID: 29212971
[TBL] [Abstract][Full Text] [Related]
9. Reversible pre-capillary pulmonary hypertension due to dasatinib.
Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.
Weatherald J; Chaumais MC; Savale L; Jaïs X; Seferian A; Canuet M; Bouvaist H; Magro P; Bergeron A; Guignabert C; Sitbon O; Simonneau G; Humbert M; Montani D
Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28751413
[TBL] [Abstract][Full Text] [Related]
11. Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
Hong JH; Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Park JE; Jeon HR; Oh YJ; Yi JE; Jung HO; Youn HJ; Kim DW
Cancer Res Treat; 2015 Oct; 47(4):937-42. PubMed ID: 25648097
[TBL] [Abstract][Full Text] [Related]
12. [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].
Liu B; Wang Y; Mi Y; Wang J
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):581-6. PubMed ID: 25052596
[TBL] [Abstract][Full Text] [Related]
13. Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension.
Toya T; Nagatomo Y; Kagami K; Yukino M; Yasuda R; Namba T; Ido Y; Kobayashi S; Masaki N; Yada H; Kimura F; Adachi T
Int J Cardiovasc Imaging; 2019 Aug; 35(8):1435-1442. PubMed ID: 30715668
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H
Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544
[TBL] [Abstract][Full Text] [Related]
15. Is dasatinib-related pulmonary hypertension a clinical concern?
Szmit S
Future Oncol; 2015 Sep; 11(18):2491-4. PubMed ID: 26278893
[No Abstract] [Full Text] [Related]
16. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Kojima M; Nakamura N; Amaki J; Numata H; Miyaoka M; Motoori T; Matsumoto K; Ando K
J Clin Exp Hematop; 2017; 57(2):69-73. PubMed ID: 29021516
[TBL] [Abstract][Full Text] [Related]
17. [Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report].
Makeeva LM; Emelina EI; Gendlin GE; Nikitin IG; Vasyuk YA; Nesvetov VV
Kardiologiia; 2017 Apr; 57(S4):53-60. PubMed ID: 29466183
[TBL] [Abstract][Full Text] [Related]
18. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Guignabert C; Phan C; Seferian A; Huertas A; Tu L; Thuillet R; Sattler C; Le Hiress M; Tamura Y; Jutant EM; Chaumais MC; Bouchet S; Manéglier B; Molimard M; Rousselot P; Sitbon O; Simonneau G; Montani D; Humbert M
J Clin Invest; 2016 Sep; 126(9):3207-18. PubMed ID: 27482885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
